The fight against obstructive sleep apnea (OSA) has taken a monumental leap forward. For the first time, the U.S. Food and ...

The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly (LLY ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

Sleep apnea is a condition in which breathing stops intermittently while a person sleeps. Read more at straitstimes.com.

The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

U.S. regulators have approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for ...